\
&
Contact us
\
&
Contact us
Published on | 8 months ago
Programmes HealthThe European Medicines Agency (EMA) has made available a new clinical trial map, which is now accessible from the public website of the Clinical Trials Information System (CTIS). The map is designed to provide patients and healthcare professionals with easy access to comprehensive, real-time information about clinical trials conducted in their area, increasing access to clinical research in the European Union. Users can look for ongoing trials by geographic area and medical condition. The first version of the map is provided in English. Additional EU languages will be added in the future.
A recording with a demonstration on how to use all the features is available on the EMA website. More information here.
Background: The creation of the map is an action of the Accelerating Clinical Trials in the European Union (ACT EU) initiative workplan for 2025-2026. CTIS includes a public searchable database for healthcare professionals, patients and citizens to deliver the high level of transparency foreseen by the Clinical Trials Regulation. The authorisation and oversight of clinical trials is the responsibility of EU/EEA Member States while EMA is responsible for maintaining CTIS. The European Commission oversees the implementation of the Clinical Trials Regulation.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Textgain is a Flemish SME and a partner in Digital Europe project BENEDMO, which answered to call ‘European Digital Media observatory (EDMO) - National and multinational hubs’.
Its task within the project is to further develop technologies to effectively detect sources of polarisation and disinformation, allowing journalists and moderators to quickly mitigate the harmful effects of such messages.
